易威 (1799.TWO)

63.60 -3.10 (-4.65%) 收市：01:30PM CST

易威

No.10, Yanfa 2nd Road
Hsinchu Science Park
Hsinchu City 30076
Taiwan
886 3 666 9596
https://www.easywellbio.com

版塊: Healthcare
行業: Medical Devices
全職員工: 

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. James Lee Ph.D.	President	無	無	無
Dr. Yu-Hsing Tu Ph.D.	Chief Science Officer	無	無	無
Dr. She Bin-Ru Ph.D.	Chief Technical Officer of Regenerative Medicine Division	無	無	無

截止 為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 TWD。

描述

Easywell Biomedicals, Inc. develops, manufactures, and sells active pharmaceutical ingredients and over-the-counter drug products in the United States and Asia. It develops TLX-001, an anti-cough medicine; TLX-005, an anti-urinary incontinence medicine; TLX-006 for treatment of breast cancer in PMS women; TLX-007 and TLX-004, an anti-depressant; TLX-008 for prevention of pneumocystis pneumonia; TLX-012 for treatment of epilepsy; TLX-017 for treatment of chronic angina; and TLX-011 for treatment of inflammatory lesions of rosacea. The company also develops TWB-201 for Parkinson patch; TLX-501, an urinary medicine; and TLX-502, a pneumonia medicine. In addition, it provides medical devices. The company was formerly known as Actherm Inc. and changed its name to Easywell Biomedicals, Inc. in July 2015. Easywell Biomedicals, Inc. was incorporated in 1998 and is headquartered in Hsinchu City, Taiwan.

公司管治

截至 無 止，易威 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。